Tokyo, Japan

Shigeki Kunikawa

USPTO Granted Patents = 6 

 

 

Average Co-Inventor Count = 10.5

ph-index = 2

Forward Citations = 57(Granted Patents)


Location History:

  • Chuo-ku, JP (2011)
  • Tokyo, JP (2013 - 2020)

Company Filing History:


Years Active: 2011-2020

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovations of Shigeki Kunikawa

Introduction

Shigeki Kunikawa, an accomplished inventor based in Tokyo, Japan, has made significant contributions to the field of pharmaceuticals, particularly in the treatment of lung cancer. With a portfolio of six patents, Kunikawa's work stands out for its innovative approaches to complex medical challenges.

Latest Patents

Among his latest patents, Kunikawa focuses on a quinazoline compound that serves as an active ingredient in a pharmaceutical composition for treating lung cancer. The compound demonstrates exceptional inhibitory activity against the G12C mutation of the KRAS gene, which is known to play a role in the development of various cancers. The discovery highlights the potential of this quinazoline compound and its salts as therapeutic agents for lung cancer, providing new hope in cancer treatment.

Career Highlights

Kunikawa is currently associated with Astellas Pharma GmbH, where he applies his expertise in drug development and innovation. His career has been marked by a commitment to advancing medical science through the creation of effective pharmaceutical compositions.

Collaborations

Throughout his professional journey, Shigeki Kunikawa has collaborated with esteemed colleagues such as Tomoyoshi Imaizumi and Kazuyuki Kuramoto. These partnerships have been pivotal in driving forward research and innovation, optimizing the processes required to bring new compounds to market.

Conclusion

In summary, Shigeki Kunikawa's innovative spirit and dedication to pharmaceutical research uniquely position him as a notable inventor in the field. His contributions, particularly in developing a quinazoline compound for lung cancer treatment, illustrate the impact of his work on advancing medical solutions. As he continues to collaborate and innovate, the medical community looks forward to the promising results of his research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…